Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Narrative) (Details)

v3.7.0.1
Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Mar. 07, 2017
Issuance of common stock Pelican, shares     1,331,056    
Revenue $ 411,250 $ 435,490  
Net loss (income) $ (3,218,915) $ (2,925,221) $ (6,408,853) $ (7,484,825)  
Pelican Therapeutics, Inc. [Member]          
Percentage of voting interests acquired in acquisition 80.00%   80.00%   80.00%
Issuance of common stock Pelican, shares     1,331,056    
Percentage of outstanding common shares issued for equity consideration in business acquisition     4.99%    
In-process R&D     $ 5,866,000    
Fees and expenses associated with acquisition     $ 559,000    
Percentage of non-controlling interest acquired 20.00%   20.00%    
Revenue     $ 411,250    
Net loss (income)     $ 72,252